University of Bristol research could lead to better detection of the most common type of malignant brain cancer.
The development of a simple blood test for glioblastomas (GBMs) could mean earlier diagnosis and more effective and personalized treatment options.
The Bristol-led research, published in the Journal of the Royal Society Interface, involved the development of mathematical models to assess the current use of biomarkers in the detection of GBMs and how such biomarker-based strategies can be improved.
This research is part of a wider University of Bristol-led CRUK project to develop an affordable point-of-care blood test to diagnose brain tumors. This cross-disciplinary project combines biomarker discovery, development of fluorescent nanoparticle and new testing techniques with computational modeling.
In this recent study, mathematical models were developed and paired with experimental data. The researchers found that for the prospective GBM biomarker Glial fibrillary acidic protein (GFAP) lowering the current biomarker threshold could lead to earlier detection of GBMs. The team also used computational modeling to explore the impact of tumor characteristics and patient differences on detection and strategies for improvements.
Dr. Johanna Blee, lead author and Research Associate in the University of Bristol’s Department of Engineering Mathematics, said, “Our findings provide the basis for further clinical data on the impact of lowering the current detection threshold for the known biomarker, GFAP, to allow earlier detection of GBMs using blood tests. With further experimental data, it may also be possible to quantify tumor and patient heterogeneities and incorporate errors into our models and predictions for blood levels for different tumors. We have also demonstrated how our models can be combined with other diagnostics such as scans to enhance clinical insight with a view to developing more personalized and effective treatments.
Source: Read Full Article